StockNews.com Initiates Coverage on Can-Fite BioPharma (NYSE:CANF)

Investment analysts at StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANFGet Free Report) in a research note issued to investors on Friday. The firm set a “hold” rating on the stock.

Can-Fite BioPharma Stock Performance

NYSE:CANF opened at $2.22 on Friday. The firm has a market cap of $7.86 million, a PE ratio of -1.24 and a beta of 1.52. Can-Fite BioPharma has a fifty-two week low of $1.52 and a fifty-two week high of $3.33. The business has a 50 day moving average price of $2.11 and a 200-day moving average price of $2.17.

Hedge Funds Weigh In On Can-Fite BioPharma

Several hedge funds have recently bought and sold shares of the business. Schechter Investment Advisors LLC purchased a new stake in Can-Fite BioPharma in the fourth quarter valued at about $44,000. Virtu Financial LLC purchased a new stake in Can-Fite BioPharma in the second quarter valued at about $52,000. Finally, Armistice Capital LLC purchased a new stake in Can-Fite BioPharma in the fourth quarter valued at about $340,000. Institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.

See Also

Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.